Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therap...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2022-05-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actadv/article/view/206 |
| _version_ | 1818232528460316672 |
|---|---|
| author | Marloes E. van Muijen Sarah E. Thomas Hans M.M. Groenewoud Marisol E. Otero Paul M. Ossenkoppele Marcellus D. Njoo Sharon R.P. Dodemont Else N. Kop Maartje A.M. Berends Marjolein I.A. Koetsier Johannes M. Mommers John E.M. Körver Ron A. Tupker Marjolein S. de Bruin-Weller Lizelotte J.M.T. Weppner-Parren Bas Peters Marloes M. Kleinpenning Astrid L.A. Kuijpers W. Peter Arnold Paula P.M. van Lümig Juul M.P.A. van den Reek Elke M.G.J. de Jong |
| author_facet | Marloes E. van Muijen Sarah E. Thomas Hans M.M. Groenewoud Marisol E. Otero Paul M. Ossenkoppele Marcellus D. Njoo Sharon R.P. Dodemont Else N. Kop Maartje A.M. Berends Marjolein I.A. Koetsier Johannes M. Mommers John E.M. Körver Ron A. Tupker Marjolein S. de Bruin-Weller Lizelotte J.M.T. Weppner-Parren Bas Peters Marloes M. Kleinpenning Astrid L.A. Kuijpers W. Peter Arnold Paula P.M. van Lümig Juul M.P.A. van den Reek Elke M.G.J. de Jong |
| author_sort | Marloes E. van Muijen |
| collection | DOAJ |
| description | Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therapies for psoriasis, corrected for confounders. This prospective, multicentre cohort study assessed BioCAPTURE data on etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab in 1,080 treatment episodes of 700 patients with psoriasis. The course of the mean absolute Psoriasis Area and Severity Index (PASI) and the proportion of patients who achieved PASI90/PASI75 were compared using linear mixed models and mixed logistic regression models respectively, corrected for baseline PASI, biologic naivety, and weight. Patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASI90 than those treated with etanercept. Patients treated with ixekizumab or guselkumab also had higher probabilities of reaching PASI90 than adalimumab, ustekinumab, and secukinumab. Relative to randomized controlled trials, the proportions of patients who reached PASI90/75 were lower in this real-world study.
|
| first_indexed | 2024-12-12T11:07:43Z |
| format | Article |
| id | doaj.art-e146b3b81ecf4e69ba49684069d330cc |
| institution | Directory Open Access Journal |
| issn | 0001-5555 1651-2057 |
| language | English |
| last_indexed | 2024-12-12T11:07:43Z |
| publishDate | 2022-05-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj.art-e146b3b81ecf4e69ba49684069d330cc2022-12-22T00:26:23ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572022-05-0110210.2340/actadv.v102.206Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre CohortMarloes E. van Muijen0Sarah E. ThomasHans M.M. GroenewoudMarisol E. OteroPaul M. OssenkoppeleMarcellus D. NjooSharon R.P. DodemontElse N. KopMaartje A.M. BerendsMarjolein I.A. KoetsierJohannes M. MommersJohn E.M. KörverRon A. TupkerMarjolein S. de Bruin-WellerLizelotte J.M.T. Weppner-ParrenBas PetersMarloes M. KleinpenningAstrid L.A. KuijpersW. Peter ArnoldPaula P.M. van LümigJuul M.P.A. van den ReekElke M.G.J. de JongDepartment of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, NL-6500 HB Nijmegen, The NetherlandsReal-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therapies for psoriasis, corrected for confounders. This prospective, multicentre cohort study assessed BioCAPTURE data on etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab in 1,080 treatment episodes of 700 patients with psoriasis. The course of the mean absolute Psoriasis Area and Severity Index (PASI) and the proportion of patients who achieved PASI90/PASI75 were compared using linear mixed models and mixed logistic regression models respectively, corrected for baseline PASI, biologic naivety, and weight. Patients treated with adalimumab, ustekinumab, secukinumab, ixekizumab, or guselkumab all had a significantly lower mean PASI after 12 months compared with etanercept, and significantly higher overall odds of reaching PASI90 than those treated with etanercept. Patients treated with ixekizumab or guselkumab also had higher probabilities of reaching PASI90 than adalimumab, ustekinumab, and secukinumab. Relative to randomized controlled trials, the proportions of patients who reached PASI90/75 were lower in this real-world study. https://medicaljournalssweden.se/actadv/article/view/206psoriasisbiologicsPASIreal world evidenceeffectivenessobservational studies |
| spellingShingle | Marloes E. van Muijen Sarah E. Thomas Hans M.M. Groenewoud Marisol E. Otero Paul M. Ossenkoppele Marcellus D. Njoo Sharon R.P. Dodemont Else N. Kop Maartje A.M. Berends Marjolein I.A. Koetsier Johannes M. Mommers John E.M. Körver Ron A. Tupker Marjolein S. de Bruin-Weller Lizelotte J.M.T. Weppner-Parren Bas Peters Marloes M. Kleinpenning Astrid L.A. Kuijpers W. Peter Arnold Paula P.M. van Lümig Juul M.P.A. van den Reek Elke M.G.J. de Jong Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort Acta Dermato-Venereologica psoriasis biologics PASI real world evidence effectiveness observational studies |
| title | Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort |
| title_full | Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort |
| title_fullStr | Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort |
| title_full_unstemmed | Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort |
| title_short | Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort |
| title_sort | direct comparison of real world effectiveness of biologics for psoriasis using absolute and relative psoriasis area and severity index scores in a prospective multicentre cohort |
| topic | psoriasis biologics PASI real world evidence effectiveness observational studies |
| url | https://medicaljournalssweden.se/actadv/article/view/206 |
| work_keys_str_mv | AT marloesevanmuijen directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT sarahethomas directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT hansmmgroenewoud directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT marisoleotero directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT paulmossenkoppele directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT marcellusdnjoo directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT sharonrpdodemont directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT elsenkop directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT maartjeamberends directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT marjoleiniakoetsier directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT johannesmmommers directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT johnemkorver directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT ronatupker directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT marjoleinsdebruinweller directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT lizelottejmtweppnerparren directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT baspeters directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT marloesmkleinpenning directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT astridlakuijpers directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT wpeterarnold directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT paulapmvanlumig directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT juulmpavandenreek directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort AT elkemgjdejong directcomparisonofrealworldeffectivenessofbiologicsforpsoriasisusingabsoluteandrelativepsoriasisareaandseverityindexscoresinaprospectivemulticentrecohort |